Combined angiotensin converting enzyme inhibition and angiotensin AT1 receptor blockade up-regulates myocardial AT2 receptors in remodeled myocardium post-infarction

Cardiovascular Research

Volumn 51, Issue 1, 2001, Pages 131-139

  Lee, Sunghou ^a   Kramer, Christopher M ^b   Mankad, Sunil ^c   Yoo, Sung Eun ^d   Sandberg, Kathryn ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c Department of Medicine   (United States)

^d Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

ACE inhibitors; Angiotensin; Antihypertensive diuretic agents; Infarction; Receptors; Remodeling; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; LOSARTAN; RADIOLIGAND; RAMIPRIL; RECEPTOR SUBTYPE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; HEART INFARCTION; HEART MUSCLE; HYPOTHESIS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR UPREGULATION;

ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DRUG THERAPY, COMBINATION; FEMALE; IMIDAZOLES; LOSARTAN; MODELS, ANIMAL; MYOCARDIAL INFARCTION; MYOCARDIUM; PYRIDINES; RADIOLIGAND ASSAY; RAMIPRIL; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; REGRESSION ANALYSIS; SHEEP; VENTRICULAR REMODELING;

EID: 0034995365     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00267-X     Document Type: Article

References (49)

1. AT1-receptor blockers in hypertension and heart failure: Clinical experience and future directions
2. Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension
3. Physiological and pharmacological implications of AT1 versus AT2 receptors
4. Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction
5. Recent insight into therapy of congestive heart failure: Focus on ACE inhibition and angiotensin-II antagonism
6. Angiotensin II receptors and angiotensin II receptor antagonists
7. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases
8. The AT2 receptor: Fact, fancy and fantasy
9. Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system
10. Angiotensin receptor subtypes in rat, rabbit and monkey tissues: Relative distribution and species dependency
11. Myocardial angiotensin receptors in human hearts
12. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression
13. Cross talk between angiotensin II type 1 and type 2 receptors: Cellular mechanism of angiotensin type 2 receptor-mediated cell growth inhibition
14. Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts
15. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction
16. Localization of the angiotensin II receptor subtypes in the human atrium
17. Subtype 2 and atypical angiotensin receptors in the human heart
18. Differential distribution of angiotensin AT2 receptors in the normal and failing human heart
19. AT1 and AT2 angiotensin receptor gene expression in human heart failure
20. Large animal model of left ventricular aneurysm
21. Regional differences in function within noninfarcted myocardium during left ventricular remodeling
22. Reduced sympathetic innervation underlies adjacent noninfarcted region dysfunction during left ventricular remodeling
23. Regional myocyte hypertrophy parallels regional myocardial dysfunction during post-infarct remodeling
24. Combining angiotensin II receptor antagonism and angiotensin converting enzyme inhibition further attenuates post-infarction left ventricular remodeling
25. Angiotensin-converting enzyme inhibition limits dysfunction in adjacent noninfarcted regions during left ventricular remodeling
26. Review of the Folin phenol protein quantitation method of Lowry, Rosebrough, Farr and Randall
27. Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1-receptor antagonist
28. 50) of an enzymatic reaction
29. Up-regulation of angiotensin II receptor expression in sheep heart after myocardial infarction
30. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril
31. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators
32. Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
33. Enhancing cardiac protection after myocardial infarction: Rationale for newer clinical trials of angiotensin receptor blockers
34. Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts
35. Angiotensin II receptor subtypes and cardiac function
36. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators
37. Effect of the angiotensin receptor blocker valsartan on morbidity and mortality in heart failure: The Valsartan heart failure trial
38. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives
39. Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide
40. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart
41. Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: Role of tissue angiotensin II
42. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart
43. Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system
44. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition
45. Determinants of angiotensin II generation during converting enzyme inhibition
46. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers
47. Cardiac-specific overexpression of angiotensin I.I. AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects
48. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation
49. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators